Background: Inflammatory bowel disease (IBD) is characterized by disturbance of pro-inflammatory cytokines and\r\nanti-inflammatory cytokines. Previous studies have demonstrated the effect of anti-inflammatory cytokines, such as\r\ninterleukin-10 (IL-10) or IL-4 on IBD, but their data were controversial. This study further investigated the effect of\r\nIL-4 (IL-4), IL-10 and their combination on treatment of trinitrobenzenesulfonic acid (TNBS)-induced murine colitis.\r\nMethods: pcDNA3.0 carrying murine IL-4 or IL-10 cDNA was encapsulated with LipofectAMINE 2000 and intraperitoneally\r\ninjected into mice with TNBS-induced colitis. The levels of intestinal IL-4 and IL-10 mRNA were confirmed by\r\nquantitative-RT-PCR. Inflamed tissues were assessed by histology and expression of interferon (IFN)-?, tumor necrosis\r\nfactor (TNF)-a and IL-6.\r\nResults: The data confirmed that IL-4 or IL-10 over-expression was successfully induced in murine colon tissues after\r\nintraperitoneal injection. Injections of IL-4 or IL-10 significantly inhibited TNBS-induced colon tissue damage, disease\r\nactivity index (DAI) and body weight loss compared to the control mice. Furthermore, expression of IFN-?, TNF-a and\r\nIL-6 was markedly blocked by injections of IL-4 or IL-10 plasmid. However, there was less therapeutic effect in mice\r\ninjected with the combination of IL-4 and IL-10.\r\nConclusions: These data suggest that intraperitoneal injection of IL-4 or IL-10 plasmid was a potential strategy in control\r\nof TNBS-induced murine colitis, but their combination had less effect.
Loading....